Trials / Completed
CompletedNCT00193531
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas. We hope to identify a "standard treatment" for this unusual group of patients who are not usually eligible for clinical trials.
Detailed description
Upon determination of eligibility, patients will be receive: * Paclitaxel + Carboplatin + Etoposide
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel | |
| DRUG | Carboplatin | |
| DRUG | Etoposide |
Timeline
- Start date
- 1998-12-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2005-09-19
- Last updated
- 2023-04-11
Source: ClinicalTrials.gov record NCT00193531. Inclusion in this directory is not an endorsement.